![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
T-Cell leukemias and lymphomas represent a less common and heterogeneous group of lymphoid neoplasms. Overall, they respond less well to chemotherapy and have a poorer prognosis than their B-cell counterparts. T-Cell tumors express a number of potential targets for receptor-directed antibody therapy; however, there is no available therapeutic monoclonal antibody for these diseases with comparable activity to that of rituximab in B-cell disorders. Despite this, alemtuzumab, a humanized anti-CD52 monoclonal antibody has demonstrated meaningful anti-tumor activity in a variety of T-cell malignancies. A number of other antibodies, modified antibodies and immunotoxins directed against targets such as CD2, CD4, CD5, CD25, CD30 and CD122 expressed on malignant T-cells are under investigation. The current status of receptor-directed antibody therapy for T-cell leukemia and lymphoma is reviewed.
| Abbreviations | ||
| ACID, | = | Activation-induced cell death |
| ATL, | = | Adult T-cell leukemia/lymphoma |
| ALCL, | = | Anaplastic large cell lymphoma |
| ADCC, | = | Antibody-dependent cellular cytotoxicity |
| AIL, | = | Angioimmunoblastic T-cell lymphoma |
| CD, | = | Cluster designation |
| CHOP, | = | Cyclophosphamide, doxorubicin, vincristine and prednisone |
| CTCL, | = | Cutaneous T-cell lymphoma |
| CMV, | = | Cytomegalovirus |
| CLL, | = | Chronic lymphocytic leukemia |
| DT, | = | Diphtheria toxin |
| EPOCH, | = | Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin |
| EBV-LPD, | = | Epstein-Barr virus-related B-cell lymphoproliferative disease, GPI, Glycophosphoinositol |
| GvHD, | = | Graft-versus-host disease |
| HAMA, | = | Human anti-mouse antibodies |
| HL, | = | Hodgkin's lymphoma |
| HTLV-1, | = | Human T-cell lymphotrophic virus type-1 |
| IL, | = | Interleukin |
| JAK, | = | Janus kinase |
| Kd, | = | Dissociation constant |
| LAK, | = | Lymphokine-activated killer |
| LFA, | = | Lymphocyte function antigen |
| MHC, | = | Major histocompatibility complex, NK, natural killer |
| NOD/SCID, | = | non-obese diabetic/severe combined immunodeficiency |
| PE, | = | Pseudomonas exotoxin A |
| PTCL, | = | Peripheral T-cell lymphoma |
| LGL, | = | large granular lymphocyte |
| T-PLL, | = | T-cell prolymphocytic leukemia |
| TCR, | = | T-cell receptor |
| TNFα, | = | Tumor necrosis factor-alpha |
| WHO, | = | World Health Organization |
| Abbreviations | ||
| ACID, | = | Activation-induced cell death |
| ATL, | = | Adult T-cell leukemia/lymphoma |
| ALCL, | = | Anaplastic large cell lymphoma |
| ADCC, | = | Antibody-dependent cellular cytotoxicity |
| AIL, | = | Angioimmunoblastic T-cell lymphoma |
| CD, | = | Cluster designation |
| CHOP, | = | Cyclophosphamide, doxorubicin, vincristine and prednisone |
| CTCL, | = | Cutaneous T-cell lymphoma |
| CMV, | = | Cytomegalovirus |
| CLL, | = | Chronic lymphocytic leukemia |
| DT, | = | Diphtheria toxin |
| EPOCH, | = | Etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin |
| EBV-LPD, | = | Epstein-Barr virus-related B-cell lymphoproliferative disease, GPI, Glycophosphoinositol |
| GvHD, | = | Graft-versus-host disease |
| HAMA, | = | Human anti-mouse antibodies |
| HL, | = | Hodgkin's lymphoma |
| HTLV-1, | = | Human T-cell lymphotrophic virus type-1 |
| IL, | = | Interleukin |
| JAK, | = | Janus kinase |
| Kd, | = | Dissociation constant |
| LAK, | = | Lymphokine-activated killer |
| LFA, | = | Lymphocyte function antigen |
| MHC, | = | Major histocompatibility complex, NK, natural killer |
| NOD/SCID, | = | non-obese diabetic/severe combined immunodeficiency |
| PE, | = | Pseudomonas exotoxin A |
| PTCL, | = | Peripheral T-cell lymphoma |
| LGL, | = | large granular lymphocyte |
| T-PLL, | = | T-cell prolymphocytic leukemia |
| TCR, | = | T-cell receptor |
| TNFα, | = | Tumor necrosis factor-alpha |
| WHO, | = | World Health Organization |